We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis (FUMAPMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02959658
Recruitment Status : Completed
First Posted : November 9, 2016
Last Update Posted : December 24, 2020
Sponsor:
Collaborator:
Biogen
Information provided by (Responsible Party):
Jacob L Talbot, Rigshospitalet, Denmark

Brief Summary:

This study aims to evaluate safety and efficacy of dimethyl fumarate treatment in patients with primary progressive multiple sclerosis (PPMS).

Half of the patients will receive dimethyl fumarate and the other half will receive placebo.


Condition or disease Intervention/treatment Phase
Primary Progressive Multiple Sclerosis Drug: Dimethyl fumarate Drug: Placebo Phase 2

Detailed Description:

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system and is presumed to be caused by T cell-mediated autoimmune processes. PPMS has no registered treatment options only symptomatic treatment exists. Progressive forms of MS are characterized clinically by gradual symptom development with or without superimposed relapses.

Fumarates have long been known to have disease-attenuating effects in psoriasis. They have been in routine use in dermatology in Germany for several decades. Dimethyl fumarate has the interesting property of combining immunological effects, at least partly mediated by interference with nuclear factor kappa B and other transcription factors, and also anti-oxidative and neuroprotective effects mediated by activation of the transcription factor Nuclear factor (erythroid-derived 2)-Related Factor 2 (NRF2). Dimethyl fumarate is currently approved for treatment of relapsing-remitting MS by the European medicines Agency in a dose of 240 mg twice per day.

Neurofilament light chain (NFL) is a treatment responsive biomarker of neuronal and axonal death when appearing in the cerebrospinal fluid (CSF) and it has been associated with long-term prognosis in MS. The concentration is often elevated in progressive MS patients. Treatment effect is measured by measuring changes in neurofilament light chain concentration over the course of 48 weeks of treatment with either active drug or placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
Actual Study Start Date : December 2016
Actual Primary Completion Date : December 21, 2019
Actual Study Completion Date : December 9, 2020


Arm Intervention/treatment
Active Comparator: Active drug
Dimethyl fumarate, 240mg twice daily for 48 weeks
Drug: Dimethyl fumarate
Other Names:
  • Tecfidera
  • BG-12

Placebo Comparator: Placebo
Placebo Oral Capsules, 2 tablets twice daily for 48 weeks
Drug: Placebo
Manufactured to mimic Dimethyl Fumarate capsules




Primary Outcome Measures :
  1. Neurofilament light chain in the cerebrospinal fluid (CSF) [ Time Frame: 0-48 weeks ]
    CSF Neurofilament Light Chain (NFL) is measured twice over a course of 48 weeks. Patients will have a spinal tap performed at baseline and again at week 48.


Secondary Outcome Measures :
  1. Expanded Disability Status Scale (EDSS) [ Time Frame: 0-48 weeks ]
    We will analyze the difference in EDSS change from screening visit to week 48 between the treatment and placebo group. EDSS is performed by a certified physician, primarily the PI.

  2. Timed 25-Foot Walk (T25FW) [ Time Frame: 0-48 weeks ]
    We will analyze the difference in T25FW change from screening visit to week 48 between the treatment and placebo group. T25FW is evaluated by the principal investigator or a delegated member of the study team.

  3. Nine hole peg test (9HPT) [ Time Frame: 0-48 weeks ]
    We will analyze the difference in 9HPT change from screening visit to week 48 between the treatment and placebo group. 9HPT is evaluated by the principal investigator or a delegated member of the study team.

  4. Symbol digit modalities test (SDMT) [ Time Frame: 0-48 weeks ]
    We will analyze the difference in the SDMT change from screening visit to week 48 between the treatment and placebo group using a general linear model with treatment allocation as factor and the screening SDMT value as covariate. SDMT is evaluated by the principal investigator or a delegated member of the study team.

  5. CSF/Serum Immunoglobulin type G index [ Time Frame: 0-48 weeks ]
    Is assessed from a sample of the cerebrospinal fluid at baseline and at week 48 and change is recorded. The analysis will be performed by the routine diagnostics department at the hospital where the spinal tap is performed.

  6. Cerebrospinal fluid-serum albumin quotient [ Time Frame: 0-48 weeks ]
    We will analyze the difference in change in CSF-serum albumin quotient from screening visit to week 48 between the treatment and placebo group. The analysis will be performed by the routine diagnostics department at the hospital where the spinal tap is performed.

  7. soluble CD14 (sCD14) [ Time Frame: 0-48 weeks ]
    We will analyze the difference in change in sCD14 concentration from screening visit to week 48 between the treatment and placebo group. The analysis is performed by a multiplex luminex assay (R&D systems).

  8. soluble CD27 (sCD27) [ Time Frame: 0-48 weeks ]
    We will analyze the difference in change in sCD27 concentration from screening visit to week 48 between the treatment and placebo group. The analysis is performed by a multiplex luminex assay (R&D systems).

  9. BCMA [ Time Frame: 0-48 weeks ]
    We will analyze the difference in change in BCMA concentration from screening visit to week 48 between the treatment and placebo group. The analysis is performed by a multiplex luminex assay (R&D systems).

  10. Chitinase 3-like-1 [ Time Frame: 0-48 weeks ]
    We will analyze the difference in change in CHI3L1 concentration from screening visit to week 48 visit between the treatment and placebo group. The analysis is performed by a multiplex luminex assay (R&D systems).

  11. Myelin Basic protein (MBP) [ Time Frame: 0-48 weeks ]
    We will analyze the difference in change in MBP concentration from screening visit to week 48 between the treatment and placebo group. The analysis is performed by a enzyme-linked immunosorbent assay (ELISA) (R&D DuoSet).

  12. Number of new or enlarged T2 lesions [ Time Frame: 0-48 weeks ]
    We will analyze the number of new or enlarging T2 lesions from screening visit to W48 between the treatment and placebo group. This analysis will be performed by our collaborator at Hvidovre Hospital (Danish Research Center for Magentic Resonance)

  13. Fractional anisotropy (FA) in Normal Appearing White Matter (NAWM) [ Time Frame: 0-48 weeks ]
    We will analyze the difference in change from screening to W48 of FA in NAWM between the treatment and placebo group. This analysis will be performed by our collaborator at Hvidovre Hospital (Danish Research Center for Magentic Resonance)

  14. Change in lesion volume [ Time Frame: 0-48 weeks ]
    We will analyze the change from screening to W48 in lesion volume. This analysis will be performed by our collaborator at Hvidovre Hospital (Danish Research Center for Magentic Resonance)

  15. Change from screening in in magnetization transfer ratio (MTR) of T2 lesions [ Time Frame: 0-48 weeks ]
    We will analyze the difference in change from screening to W48 in MTR of T2 lesions between the treatment and placebo group. This analysis will be performed by our collaborator at Hvidovre Hospital (Danish Research Center for Magentic Resonance).

  16. Thalamic volume [ Time Frame: 0-48 weeks ]
    We will analyze the difference in change from screening to W48 of thalamic volume between the treatment and placebo group. This analysis will be performed by our collaborator at Hvidovre Hospital (Danish Research Center for Magentic Resonance).

  17. Percent brain volume change (PBVC) [ Time Frame: 0-48 weeks ]
    We will analyze the difference in percentage change in brain volume from screening visit to week 48 between the treatment and placebo group. This analysis will be performed by our collaborator at Hvidovre Hospital (Danish Research Center for Magentic Resonance).


Other Outcome Measures:
  1. BVMTR [ Time Frame: 0-48 weeks & 48-96 weeks ]
    Change from screening for Brief Visuospatial Memory Test Revised (BVMTR) The test is performed by the principal investigator or a delegated member of the study team.

  2. California Verbal Learning Test 2 (CVLT-II) [ Time Frame: 0-48 weeks & 48-96 weeks ]
    Change from screening for California Verbal Learning Test 2 (CVLT-II). The test is performed by the principal investigator or a delegated member of the study team.

  3. UDI [ Time Frame: 0-48 weeks & 48-96 weeks ]
    The questionnaire is handed out at screening visit, week 48 and week 96.

  4. FSMC [ Time Frame: 0-48 weeks & 48-96 weeks ]
    The questionnaire is handed out at screening visit, week 48 and week 96.

  5. MSIS-29 [ Time Frame: 0-48 weeks & 48-96 weeks ]
    The questionnaire is handed out at screening visit, week 48 and week 96.

  6. Number of Gadolinium (Gd) enhancing lesions on MRI [ Time Frame: 0-48 weeks & 48-96 weeks ]
    Change from screening/W48 in number of Gd-enhancing lesions.

  7. Number of new T2 lesions [ Time Frame: 48-96 weeks ]
    Change from screening in number of new T2 lesions

  8. Number of enlarged T2 lesions [ Time Frame: 48-96 weeks ]
    Change from screening in number of enlarged T2 lesions

  9. Brain volume change [ Time Frame: 0-48 weeks & 48-96 weeks ]
    Change from screening/W48 in volume of cortical grey matter (CGM), normal appearing white matter (NAWM), thalamus, putamen and lesion volume.

  10. Change in Magnetization Transfer Ratio (MTR). [ Time Frame: 0-48 weeks & 48-96 weeks ]
    Change from screening/W48 in Magnetization Transfer Ratio (MTR) of CGM, NAWM, the putamen and thalamic nuclei

  11. Change in diffusion tensor imaging (DTI) measures (FA and mean diffusivity). [ Time Frame: 0-48 weeks & 48-96 weeks ]
    Change from screening/W48 in diffusion tensor imaging (DTI) measures (FA and mean diffusivity) of CGM, NAWM (except FA in NAWM from screening to week 48), lesions, the putamen and thalamic nuclei.

  12. Cross sectional area at C2 level of the cervical spinal cord on MRI [ Time Frame: 0-48 weeks & 48-96 weeks ]
    Change from screening/W48 in the cross sectional area at the C2 level of the cervical spinal cord on MRI.

  13. Circle drawing test at the time of the MRI [ Time Frame: 0-48 weeks & 48-96 weeks ]
    At the time of MRI (screening, week 48 and week 96) a circle drawing test will be performed.

  14. Change in Serum Neurofilament Light Chain (serum NFL) [ Time Frame: 0-48 weeks & 48-96 weeks ]
    Is assessed from a blood sample at screening visit, W48 visit, and W96 visit. The analysis is performed by the neuroimmunology laboratory with a commercially available SIMOA-assay (Quanterix).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 to 65 years
  • PPMS according to the McDonald (2010) and Lublin (2014) criteria
  • Disease duration at least one year
  • EDSS ≤ 6.5
  • Written informed consent to study participation
  • No other signs of significant disease judged by the investigator
  • Eligible for randomization to active treatment or placebo as assessed by CSF NFL levels above 380ng/L
  • Not eligible for randomization as assessed by CSF biomarker studies but accepts follow-up and open-label treatment per protocol
  • Patients not eligible for randomization due to low NFL concentrations in CSF at screening can be followed up after 48 weeks, and are eligible for open-label treatment if they fulfil one of the following clinical criteria of disease progression:
  • 1 point increase in EDSS score from screening to week 48 if screening EDSS <6
  • 0.5 point increase in EDSS score from screening to week 48 if screening EDSS>5.5
  • 2 point increase in a physical functional system
  • Worsening in SDMT, 9HPT or T25FW >20% from screening to week 48

Exclusion Criteria:

  • Pregnancy or breast feeding
  • Lack of effective contraception for women of child-bearing potential
  • Relapse within 6 months of inclusion
  • Methylprednisolone treatment within 3 months of inclusion
  • Treatment with interferon-beta, glatiramer acetate, immunoglobulin G or other immunomodulatory treatment within 6 months of inclusion
  • Treatment with mitoxantrone, cyclophosphamide, azathioprine or other immunosuppressive treatment within 6 months of inclusion
  • Findings on the screening MRI judged to preclude participation by the treating physician
  • Other diseases associated with immunodeficiency
  • Other diseases judged to be relevant by the treating physician
  • Anticoagulant therapy other than platelet inhibitors
  • Active malignant disease in the previous 5 years
  • Renal insufficiency or blood creatinine > 150 μmol/l
  • Present or chronic infection with hepatitis B virus, hepatitis C virus, HIV (tested in the screening blood samples) or other infections found to be relevant by the treating physician.
  • Psychiatric disorders or other disorders impairing the patient's ability to participate in the trial
  • Contraindication to MRI
  • Known allergy or hypersensitivity to dimethyl fumarate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02959658


Locations
Layout table for location information
Denmark
Danish Multiple Sclerosis Center, Department of neurology
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Biogen
Investigators
Layout table for investigator information
Principal Investigator: Jacob Lando Talbot, MD Rigshospitalet, Denmark
  Study Documents (Full-Text)

Documents provided by Jacob L Talbot, Rigshospitalet, Denmark:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jacob L Talbot, Principal Investigator, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT02959658    
Other Study ID Numbers: FUMAPMS2016
First Posted: November 9, 2016    Key Record Dates
Last Update Posted: December 24, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Dimethyl Fumarate
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs